68
Participants
Start Date
September 30, 2004
Primary Completion Date
October 31, 2007
Study Completion Date
September 30, 2008
Brivanib
Tablets, Oral, 180 mg, once daily, until disease progression
Brivanib
Tablets, Oral, 320 mg, once daily, until disease progression
Brivanib
Tablets, Oral, 600 mg, once daily, until disease progression
Brivanib
Tablets, Oral, 800 mg, once daily, until disease progression
Brivanib
Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
Brivanab
Tablets, Oral, 1000 mg, once daily, until disease progression
Local Institution, Milan
Indiana University Med Center, Indianapolis
University Of Wisconsin Comprehensive Center, Madison
Premiere Oncology, Santa Monica
Local Institution, Edmonton
Local Institution, Ottawa
Local Institution, Middlesex
Local Institution, Manchester
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY